284 related articles for article (PubMed ID: 36852108)
21. Growing challenge of post-liver transplantation non-alcoholic fatty liver disease.
Kalogirou MS; Giouleme O
World J Transplant; 2022 Sep; 12(9):281-287. PubMed ID: 36187880
[TBL] [Abstract][Full Text] [Related]
22. NAFLD and liver transplantation: Disease burden, current management and future challenges.
Burra P; Becchetti C; Germani G
JHEP Rep; 2020 Dec; 2(6):100192. PubMed ID: 33163950
[TBL] [Abstract][Full Text] [Related]
23. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation.
Miyaaki H; Miuma S; Taura N; Shibata H; Sasaki R; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
Transplantation; 2019 Jan; 103(1):109-112. PubMed ID: 29894414
[TBL] [Abstract][Full Text] [Related]
25. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
[TBL] [Abstract][Full Text] [Related]
26. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database.
Boursier J; Shreay S; Fabron C; Torreton E; Fraysse J
EClinicalMedicine; 2020 Aug; 25():100445. PubMed ID: 32775971
[TBL] [Abstract][Full Text] [Related]
27. NASH After Liver Transplantation: Impact of Immunosuppression.
Taneja S; Roy A; Duseja A
J Clin Exp Hepatol; 2023; 13(5):835-840. PubMed ID: 37693259
[TBL] [Abstract][Full Text] [Related]
28. Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis.
Vallin M; Guillaud O; Boillot O; Hervieu V; Scoazec JY; Dumortier J
Liver Transpl; 2014 Sep; 20(9):1064-71. PubMed ID: 24961607
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?
Mikolasevic I; Filipec-Kanizaj T; Mijic M; Jakopcic I; Milic S; Hrstic I; Sobocan N; Stimac D; Burra P
World J Gastroenterol; 2018 Apr; 24(14):1491-1506. PubMed ID: 29662288
[TBL] [Abstract][Full Text] [Related]
30. Post-transplant Non-alcoholic Fatty Liver Disease and Metabolic Syndrome After Living Donor Liver Transplantation in Indians.
Choudhary NS; Dhampalwar S; Saraf N; Rastogi A; Bhangui P; Soin AS
J Clin Exp Hepatol; 2024; 14(2):101281. PubMed ID: 38076440
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.
Haldar D; Kern B; Hodson J; Armstrong MJ; Adam R; Berlakovich G; Fritz J; Feurstein B; Popp W; Karam V; Muiesan P; O'Grady J; Jamieson N; Wigmore SJ; Pirenne J; Malek-Hosseini SA; Hidalgo E; Tokat Y; Paul A; Pratschke J; Bartels M; Trunecka P; Settmacher U; Pinzani M; Duvoux C; Newsome PN; Schneeberger S;
J Hepatol; 2019 Aug; 71(2):313-322. PubMed ID: 31071367
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
33. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
34. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
35. Liver transplantation for non-alcoholic fatty liver disease.
Germani G; Becchetti C
Minerva Gastroenterol Dietol; 2018 Jun; 64(2):138-146. PubMed ID: 29249127
[TBL] [Abstract][Full Text] [Related]
36. Liver transplantation and non-alcoholic fatty liver disease.
Zezos P; Renner EL
World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
[TBL] [Abstract][Full Text] [Related]
37. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft.
Liu A; Galoosian A; Kaswala D; Li AA; Gadiparthi C; Cholankeril G; Kim D; Ahmed A
J Clin Transl Hepatol; 2018 Dec; 6(4):420-424. PubMed ID: 30637220
[TBL] [Abstract][Full Text] [Related]
39. How will NAFLD change the liver transplant landscape in the 2020s?
Villeret F; Dumortier J; Erard-Poinsot D
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101759. PubMed ID: 34311133
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
